Children · 2022 · 21 citations · 12 references
Life SciencesDermatologyPharmacotherapyHuman GeneticsHypersensitivityPediatric DermatologyPruritic Skin DiseasePruritus ManagementAntihistamine TreatmentDermatologic Adverse EventsDrug-induced PruritusEliminationPruritic DermatosesTreatment Strategies
The patient was a 26-year-old male. He had red and scaling skin of the entire body since birth, as well as an elevated level of serum IgE. Genetic testing revealed a mutation in the SPINK5 gene, which had confirmed the diagnosis with Netherton syndrome. He has had significant pruritis since birth, and subsequently had symptoms of sleeping disorders and concentration difficulty throughout the day. Since treatment with various antihistamines were not effective, we administered dupilumab and found that it was effective in immediate elimination of pruritus and gradual reduction of the rash. Dupilumab has been administered for one year without any adverse events or recurrence of symptoms. Although studies have previously described cases who used dupilumab for Netherton syndrome, reported effects have been limited or transient. Additional studies are needed to confirm the effect of dupilumab for Netherton syndrome, which currently lack any effective treatment strategies.
12
Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch
Landon K. Oetjen, Madison R. Mack, Jing Feng et al. · Cell · 2017 · 1.1K citations · Full text
Secukinumab Therapy for Netherton Syndrome
Isabelle Luchsinger, Nicole Knöpfel, Martin Theiler et al. · JAMA Dermatology · 2020 · 112 citations · Full text
Medicine, Dermatology, Immunology +16
Treatment of Netherton Syndrome With Dupilumab
Alexa B. Steuer, David E. Cohen · JAMA Dermatology · 2020 · 59 citations
Medicine, Dermatology, Neurology +5